Brief Acceptance and Commitment Therapy for HIV-infected At-risk Drinkers

Not Applicable

Completed

• Conditions: Treatment
• Interventions: Behavioral: Brief Acceptance and Commitment Therapy; Behavioral: Brief Alcohol Intervention

• Registration Number: NCT03974061
• Lead Sponsor: Syracuse University

Brief Summary

Alcohol consumption at hazardous levels is associated with negative consequences on nearly every step of the HIV care continuum. It is a critical factor in HIV treatment that, if unaddressed, significantly contributes to onward transmission and poor treatment outcomes. Alcohol interventions for people living with HIV (PLWH) in the United States (US) have shown mixed results, and no alcohol intervention for PLHW has shown long-term reductions in heavy drinking or a significant impact on HIV-related outcomes. One hypothesized reason for this limited success is the failure of these interventions to address the multiple overlapping problems (e.g., comorbid mental health conditions, behavioral health needs) of PLWH who are hazardous drinkers. Innovative alcohol intervention strategies that can have an impact on these multiple behavioral health needs, in a format that can be feasibly delivered in the context of HIV care, are needed. Brief Acceptance and Commitment Therapy (ACT) is a promising intervention for HIV-infected hazardous drinkers. ACT is a transdiagnostic treatment that uses mindfulness skills and values-guided behavioral action plans to impact a broad array of psychological symptoms. ACT has shown efficacy for treatment of anxiety, depression, chronic pain, and substance use, making it a promising approach for hazardous drinkers. The overall objective of this application is to adapt an existing brief ACT intervention developed for smoking cessation, and pilot test its feasibility and acceptability for PLWH who are hazardous drinkers. We hypothesize that the resulting intervention will be preliminarily associated with decreased alcohol use, improved ART adherence, decreased symptoms of depression, anxiety, and drug use, and increased acceptance-a known mechanism of change in ACT.

Detailed Description

Alcohol use is a major problem in HIV care. Sixty-six percent of people living with HIV (PLWH) report using alcohol in the previous year, 8-20% report drinking at hazardous or heavy levels, and 30% report current binge drinking (\>5 drinks in an occasion in the past 30 days). PLWH who are hazardous drinkers, compared to those who abstain, experience a significant increased risk for: taking ART medications off schedule, suboptimal adherence to ART, and engaging in sexual risk behavior. Hazardous alcohol consumption has been found to affect every stage of the HIV care continuum, from diagnosis, to linkage to care, to retention, and viral suppression, making it a critical factor in HIV treatment that, if unaddressed, may significantly contribute to onward transmission.

Behavioral interventions for HIV-infected drinkers have provided limited evidence of benefit. HIV-prevention interventions do not typically address alcohol use, and it is often overlooked in HIV care. While there have been several clinical trials of alcohol interventions for PLWH in the US, these trials have shown mixed results for reducing alcohol use and improving HIV-related outcomes. No alcohol intervention for PLHW has shown long-term reductions in heavy drinking or a significant impact on HIV-related outcomes. One hypothesized reason for this limited success is that PLWH who are at-risk drinkers are also likely to have multiple overlapping problems. It is estimated that 38% of PLWH meet criteria for both a substance use and another psychiatric disorder and also have a myriad of behavioral health needs (e.g., treatment adherence, condom use), any one of which would benefit from intervention. In order to adequately address these issues, PLWH require innovative alcohol intervention strategies that can also have an impact on other behavioral and mental health needs, in a format that can be feasibly delivered in the context of HIV care.

Brief acceptance and commitment therapy (ACT) is a promising intervention for HIV-infected drinkers. ACT is a transdiagnostic treatment that targets experiential avoidance (repeated attempts to eliminate or avoid difficult thoughts/feelings) as an underlying factor common to mental and behavioral health problems. Mindfulness skills and values-guided behavioral action plans are used to decrease experiential avoidance and impact a broad array of psychological symptoms. ACT has shown efficacy for treatment of anxiety depression, and chronic pain, making it a promising approach for HIV-infected hazardous drinkers. A recently published meta-analysis also indicates that ACT is efficacious for smoking, opiate use, methamphetamine use, and polydrug abuse, showing a small to medium effect size compared to active treatment controls (e.g., Cognitive Behavioral Therapy (CBT), pharmacotherapy). ACT's unique focus on skills that increase the ability to experience and accept, rather than change and control, urges and cravings related to substance use is different from more traditional forms of addiction treatment such as CBT. Indeed, a pilot RCT of a brief, telephone-delivered ACT intervention for smoking cessation had quit rates more than double that of traditional CBT for smokers with comorbid depression. However, ACT has not been studied as an intervention for hazardous drinkers.

The overall objective of this study is to adapt an existing brief ACT intervention and pilot test its feasibility, acceptability, and preliminary efficacy for PLWH who are hazardous drinkers. We hypothesize that the resulting intervention will have a significant effect on biological and self-reported measures of alcohol use and ART adherence. Secondary analyses will also examine changes in acceptance-a known mechanism of change in ACT -symptoms of depression and anxiety, and drug use, which we expect to differ by treatment group. The specific aims are as follows:

Aim 1: Adapt an existing brief ACT intervention for HIV-infected at-risk drinkers (ACT). We will accomplish this aim by: Modifying an existing 5-session, telephone-delivered ACT intervention for smoking cessation using a theoretical framework that has been previously used to systematically adapt evidence-based HIV interventions. We will conduct iterative multidisciplinary team meetings, focus group discussions with HIV clinic patients (N = 15-20), and qualitative interviews with HIV clinic providers (N = 5-10) to inform the adaptation process, get feedback on intervention content, and develop a new treatment manual.

Aim 2: Conduct a pilot superiority trial of ACT compared to a brief alcohol intervention. We will accomplish this aim by: Randomly assigning N = 74 HIV-infected hazardous drinkers (50% women) to the intervention developed in Aim 1 (n = 30) or a brief alcohol intervention previously developed for PLWH that is nearly equivalent in number and length of sessions. We will assess feasibility, acceptability, and primary trial outcomes of alcohol use and ART adherence immediately post-treatment and again at 3 and 6-months post-randomization. Secondary outcomes of changes in acceptance, symptoms of depression, symptoms of anxiety, and drug use will be assessed at all time points.

The proposed research will provide essential pilot data for an R01 application to conduct a full-scale RCT to determine the efficacy of ACT compared with the current evidence-based treatment for PLWH. If successful, this intervention will have broad implications for implementation in HIV and other integrated care settings.

Study Timeline

• Study First Submitted: 2019-05-10
• Study First Submitted QC: 2019-05-31
• Study First Posted: 2019-06-04
• Study Start: 2019-11-01
• Primary Completion: 2022-11-10
• Study Completion: 2022-11-10
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-16
• Last Update Posted: 2023-10-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

1. ≥18 years of age,
2. HIV-positive,
3. currently prescribed ART medication,
4. score of ≥4 (men) or ≥3 (women) on the AUDIT-C.

Exclusion Criteria

1. Experiencing acute illness or declining health status when it is determined by a treatment provider that research participation is contraindicated,
2. unable to understand spoken English,
3. does not own a cell phone,
4. a score of 12 on the AUDIT-C, indicating high risk for a severe alcohol use disorder,
5. a score of ≥20 on the PHQ-9 indicating severe depressive symptoms,
6. a score of ≥15 on the GAD-7, indicating severe symptoms of anxiety,
7. experiencing active psychosis as judged by research staff via scores on the BSI.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Brief Acceptance and Commitment Therapy	Brief Acceptance and Commitment Therapy	Participants randomized to the Acceptance and Commitment Therapy (ACT) arm will receive one, 1-hour intervention session followed by five weekly 30-45 minute intervention sessions delivered via telephone.
Brief Alcohol Intervention	Brief Alcohol Intervention	Participants randomized to the Brief Alcohol Intervention (BI) will receive the following telephone-based sessions over the duration of six weeks: a 30-45 minute session of a brief alcohol intervention, a 5-10 minute booster call, a reminder phone call for the next intervention session, a 30-45 minute intervention session, a 5-10 minute booster, and a reminder phone call for the post-treatment appointment.

Primary Outcome Measures

Name	Time	Method
Change in ART adherence from 7-weeks post-treatment to 3-months post-baseline	Change in ART adherence will be measured via VAS from 7-weeks post-treatment to 3-months post-baseline.	Adherence will be measured by self-report via the validated visual analog scale (VAS) to identify participants will optimal (\>95%) versus suboptimal (\<95%) adherence. The VAS asks participants to point to the place on a line ranging from 0-100% that best represents how much of their ART medication that they have taken in the last month.
Change in ART adherence from 3-months post-baseline to 6-months post-baseline	Change in ART adherence will be measured via VAS from 3-months post-baseline to 6-months post-baseline.	Adherence will be measured by self-report via the validated visual analog scale (VAS) to identify participants will optimal (\>95%) versus suboptimal (\<95%) adherence. The VAS asks participants to point to the place on a line ranging from 0-100% that best represents how much of their ART medication that they have taken in the last month.
Change in alcohol consumption from 3-months post-baseline to 6-months post-baseline	Change in alcohol consumption will be measured via the TLFB from 3-months post-baseline to 6-months post-baseline.	Alcohol consumption will be measured by retrospective self-report via the Time Line Follow Back (TLFB) interview method which yields the following: number of drinks per drinking day, number of heavy drinking (\>3 for women; \>4 for men) episodes, and number of drinking days over the last 42-day period.
Change in alcohol consumption from baseline to 6-months post-baseline	Change in alcohol consumption will be measured via PEth from baseline to 6-months post-baseline.	Alcohol use will also be assessed using the biomarker phosphatidylethanol (PEth). PEth is an abnormal phospholipid formed only in the presence of alcohol with an estimated half-life of 4-12 days and can be measured from dried blood spots.
Change in ART adherence from baseline to 6-months post-baseline	Change in ART adherence will be measured via ARV levels in hair from baseline to 6-months post-baseline.	Adherence will also be measured via ARV levels in hair. Hair concentrations of ARVs have been shown to be the strongest independent predictor of virological success in prospective cohorts of HIV-infected patients.
Change in ART adherence from baseline to 7-weeks post-treatment	Change in ART adherence will be measured via VAS from baseline to end of treatment at 7-weeks.	Adherence will be measured by self-report via the validated visual analog scale (VAS) to identify participants will optimal (\>95%) versus suboptimal (\<95%) adherence. The VAS asks participants to point to the place on a line ranging from 0-100% that best represents how much of their ART medication that they have taken in the last month.
Change in alcohol consumption from baseline to 7-weeks post-treatment	Change in alcohol consumption will be measured via the TLFB from baseline to end of treatment at 7-weeks.	Alcohol consumption will be measured by retrospective self-report via the Time Line Follow Back (TLFB) interview method which yields the following: number of drinks per drinking day, number of heavy drinking (\>3 for women; \>4 for men) episodes, and number of drinking days over the last 42-day period.
Change in alcohol consumption from 7-weeks post-treatment to 3-months post-baseline	Change in alcohol consumption will be measured via the TLFB from 7-weeks post-treatment to 3-months post-baseline.	Alcohol consumption will be measured by retrospective self-report via the Time Line Follow Back (TLFB) interview method which yields the following: number of drinks per drinking day, number of heavy drinking (\>3 for women; \>4 for men) episodes, and number of drinking days over the last 42-day period.

Secondary Outcome Measures

Name	Time	Method
Acceptance	Acceptance will be measured at baseline, 7-weeks post-baseline, and 3 and 6-month follow-ups.	Acceptance will be measured using the total score obtained via the self-report Brief Experiential Avoidance Questionnaire (BEAQ). The BEAQ is a 15-item measures that assesses six domains of experiential avoidance: behavioral avoidance, distress aversion, procrastination, distraction, repression/denial and distress endurance.
Symptoms of Depression	Symptoms of depression will be measured at baseline, 7-weeks post-baseline, and 3 and 6-month follow-ups.	Symptoms of depression will be measured using the total score obtained via the self-report Patient Health Questionnaire (PHQ)-9. The PHQ-9 is a 10-item standardized measure of depression severity.
Symptoms of Anxiety	Symptoms of anxiety will be measured at baseline, 7-weeks post-baseline, 3 and 6-month follow-ups.	Symptoms of anxiety will be measured using the total score obtained via the self-report Generalized Anxiety Disorder 7-item (GAD-7). The GAD-7 is a 7-item standardized measure of anxiety severity.
Substance Use	Substance use will be measured at baseline, 7-weeks post-baseline, and 3 and 6-month follow-ups	Substance use will be measured by retrospective self-report via the Time Line Follow Back (TLFB) interview method which yields the number of days non-prescription drugs were used.

Trial Locations

Locations (1)

Syracuse University; 🇺🇸 Syracuse, New York, United States